Patent intelligence · US
US 11186873
Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)
Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor…
Patent details — US 11186873
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 30, 2021
- Expiration
- Nov 25, 2041
- Applicant
- Wellmarker Bio Co., LTD.
- Claims
- 15
- CPC classes
- A61K, A61K31/404, A61K31/7088, A61K31/713
Quick answer
US 11186873 (Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)) is held by Wellmarker Bio Co., LTD.. Status: granted. Granted Nov 30, 2021. Expires Nov 25, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Wellmarker Bio Co., LTD.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/404, A61K31/7088, A61K31/713, A61P, A61P1/04
More from Wellmarker Bio Co., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12077601
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
granted -
US 11885817
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11692030
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11598782
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11447500
Thienopyridine derivatives and pharmaceutical composition comprising same
granted -
US 11078298
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
granted -
US 11008622
Biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof
granted
Frequently asked questions
What is US patent 11186873?
US 11186873 (Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)) is held by Wellmarker Bio Co., LTD.. Status: granted. Granted Nov 30, 2021. Expires Nov 25, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11186873?
Wellmarker Bio Co., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 27 pharmaceutical patents for this assignee.
When does US 11186873 expire?
Our index shows an expiration date of Nov 25, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.